Remed Co.,Ltd.
Financials
Valuation Metrics
Remed Co.,Ltd.'s Market Cap is ₩789B. At end of 2025 it was ₩929B. Ranked #1435 of 2,421 in KR market (top 59%), #822 of 1,640 on KOSDAQ (top 50%), #54 of 96 in Health Care Equipment & Services (top 56%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 78.87B KRW | KR#1,435/2,421 Sec#54/96 |
| Revenue | 27.05B KRW | KR#2,066/2,421 Sec#68/96 |
| Net Income | 1.25B KRW | KR#1,461/2,421 Sec#45/96 |
| Total Assets | 53.91B KRW | KR#2,175/2,421 Sec#71/96 |
| Net Assets | 39.46B KRW | KR#2,056/2,421 Sec#71/96 |
| Employees | 104 | KR#1,613/2,421 Sec#56/96 |
| Value | ||
| P/E | 62.94x | KR#1,443/2,421 Sec#47/96 |
| P/B | 2.00x | KR#1,944/2,421 Sec#68/96 |
| P/S | 2.92x | KR#1,973/2,421 Sec#63/96 |
| EV/EBITDA | 36.62x | KR#1,265/2,421 Sec#40/96 |
| Profitability | ||
| ROE | 3.18% | KR#1,315/2,421 Sec#43/96 |
| ROA | 2.32% | KR#1,159/2,421 Sec#44/96 |
| Op. Margin | 7.22% | KR#713/2,421 Sec#34/96 |
| Revenue Growth | 10.52% | KR#875/2,421 Sec#46/96 |
| Earnings Growth | -19.42% | KR#926/2,421 Sec#37/96 |
| Financial Health | ||
| Debt Ratio | 36.60% | KR#721/2,421 Sec#34/96 |
| Total Debt | 1.12B KRW | KR#1,947/2,421 Sec#74/96 |
| Cash | 8.47B KRW | KR#1,785/2,421 Sec#58/96 |
| Current Ratio | 2.34x | KR#744/2,421 Sec#43/96 |
| Net Debt/EBITDA | -3.76x | KR#127/2,421 Sec#3/96 |
| Performance | ||
| 1Y Return | -34.63% | KR#1,698/2,421 Sec#49/96 |
| 1M Return | -8.27% | KR#2,017/2,421 Sec#73/96 |
| From 52W High | -43.31% | KR#1,074/2,421 Sec#32/96 |
| 1Y MDD | -37.64% | KR#499/2,421 Sec#13/96 |
| Trading | ||
| Volume | 16,692 shares | KR#1,667/2,421 Sec#63/96 |
| Trading Value | 43.8M KRW | KR#1,882/2,421 Sec#74/96 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/96 |
| Per Share | ||
| EPS | 41 KRW | KR#1,509/2,421 Sec#47/96 |
| BPS | 1,304 KRW | KR#2,239/2,421 Sec#83/96 |
Company Info
REMED, established in 2003 and headquartered in Cheongju-si, Chungcheongbuk-do, develops and manufactures non-invasive medical devices that induce nerve cell depolarization using strong magnetic fields. The company operates in brain rehabilitation, chronic pain treatment, and aesthetics, with its neuromodulation device for chronic pain treatment and transcranial magnetic stimulation device for brain rehabilitation having received U.S. FDA approval in 2021. REMED is targeting the global market by entering the U.S. market for TMS for depression treatment, expanding sales internationally, conducting clinical trials for mental illnesses, and premiumizing Peripheral Magnetic Stimulation products.